Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) targeting receptors like PD1 are established treatments for melanoma and NSCLC.
• These therapies have provided insights into patient response and resistance mechanisms in cancer treatment.
• Nivolumab, an anti-PD1 agent, is now a standard for platinum-refractory recurrent/metastatic HNSCC.

Purpose of the Study:

• To discuss current immune-targeting strategies for solid tumors, focusing on HNSCC.
• To outline challenges and future directions for immunotherapy in HNSCC treatment.
• To explore mechanisms of resistance to immune checkpoint receptor blockade therapy (ICR).

Main Methods:

• Review of current literature on immunotherapy in solid tumors, particularly HNSCC.
• Analysis of clinical data regarding PD1 inhibitors and their efficacy.
• Investigation into molecular pathways associated with treatment resistance.

Main Results:

• Anti-PD1 agents like nivolumab have gained FDA approval for recurrent/metastatic HNSCC.
• Research is identifying molecular pathways contributing to resistance against immunotherapy.
• Understanding resistance is crucial for selecting appropriate patients for ICR therapy.

Conclusions:

• ICR has revitalized interest in cancer immunology and treatment approaches.
• Resistance to immunotherapy is a significant clinical challenge in HNSCC.
• Further research into resistance mechanisms will guide optimal patient selection and treatment regimens.